fda on bpc 157 FDA's own advisory committee voted 8-6 Thursday. BPC-157, the compounding list now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA advisory committee recommends compounding

When administered or supervised by a provider, this is straightforward

Now, as a nurse specializing in wellness and anti-aging , she is experienced and knowledgeable about encouraging ThriveMD patients in their pursuit of optimizing their health and well-being

Benefits for Gut Health: Targets pathogens without harming beneficial bacteria Helps eliminate mold, yeast, and biofilm Improves immune surveillance in the gut lining Supports wound healing and epithelial integrity Clinical Context: LL-37 is ideal for patients with dysbiosis, recurrent infections, SIFO (small intestinal fungal overgrowth), or mold-related illness

The peptides should be reevaluated under a better process by the Pharmacy Compounding Advisory Committee, said Davis, referring to a panel that advises the FDA on issues related to drug compounding